-
Mashup Score: 47Media Centre | EASD - 5 month(s) ago
The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.
Source: www.easd.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 34Media Centre | EASD - 6 month(s) ago
The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.
Source: www.easd.orgCategories: General Medicine News, EndocrinologyTweet-
Recordings from #EASD2023 now publicly available in the EASD Media Centre! https://t.co/FdUWgztChu Take advantage of this invaluable resource and browse through 1,000's of recordings from EASD's Annual Meetings. https://t.co/ceuN5WFj0P
-
-
Mashup Score: 34Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes | NEJM - 6 month(s) ago
Original Article from The New England Journal of Medicine — Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes
Source: www.nejm.orgCategories: General Medicine News, General Journals & SocietTweet-
Original Article: Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes (AiDAPT trial) https://t.co/AlMx8VtULl Editorial: Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes https://t.co/rRFwcyi7EN #EASD2023 / @EASDnews https://t.co/qQiRhysScr
-
-
Mashup Score: 0EASD 2023 - Interview with Roman Hovorka, EASD-Novo Nordisk Foundation Diabetes Prize for Excellence - 6 month(s) ago
Duirng #EASD2023, EASD TV host Vivienne Parry talked to Roman Hovorka about his career, his research into diabetes technology and the award.Roman Hovorka is …
Source: www.youtube.comCategories: Endocrinology, Latest HeadlinesTweet-
We also talked to @_RomanHovorka during #EASD2023 about his research. Have a look at the #EASDTV interview: ▶️ https://t.co/EECbwlkarB More interviews and video highlights here: ▶️https://t.co/1RVaoUBl7I https://t.co/y7kVhRFQPE
-
-
Mashup Score: 6From NAFLD to MASLD: What's in a Name? - 6 month(s) ago
Presentations at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany, stressed the gravity of nonalcoholic fatty liver disease and the reasons for its new name.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
RT @drkevinfernando: Here's my 1st #EASD2023 @Medscape commentary piece "From NAFLD to MASLD: What's in a Name?" https://t.co/4qnh4SeJG7…
-
-
Mashup Score: 1New 'Twincretin' Pemvidutide: Another Option for Obesity - 6 month(s) ago
Unlike tirzepatide, which combines weight loss and glucose-lowering properties, this ‘twincretin’ reduces liver fat along with weight, blood pressure, and lipid levels.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet-
New '#twincretin' pemvidutide: Another option for #obesity #EASD2023 https://t.co/udLvGhFnOO https://t.co/O1xGlX16k3
-
-
Mashup Score: 0medicalportfolioapp - Official Music, Videos - Linktree - 7 month(s) ago
View medicalportfolioapp’s Linktree. Listen to their music on YouTube, Spotify here.
Source: linktr.eeCategories: Cardiologists, Latest HeadlinesTweet-
Top papers from #EASD2023! https://t.co/uRkPlbj47u #diabetes #MedEd https://t.co/NlWqKbOxfw
-
-
Mashup Score: 0
In this interactive webinar, several early career scientists from across Europe, who attended the EASD Annual Meeting 2023, will share their impressions and what they have learned during the conference.
Source: ZoomCategories: Endocrinology, Latest HeadlinesTweet-
The @EASDacademy is inviting you to join their 'Best of EASD' #webinar - A great opportunity to catch-up on some of the findings presented during #EASD2023 Register 👉 https://t.co/W6td6sYZrB #diabetes #research #education #networking https://t.co/nhvR8KGbCV
-
-
Mashup Score: 4Obesity | Radcliffe Cardiology - 7 month(s) ago
The high prevalence and increasing incidence of obesity and associated cardiovascular risk emphasises the need to focus on obesity reduction in this high-risk population. Metabolic syndrome (MetS) is the coexistence of obesity-related cardiovascular risk factors including hypertension, diabetes and dyslipidaemia. MetS is a precursor for atherosclerosis, including premature coronary artery disease, and cardiovascular mortality. This educational hub has been supported by Boehringer Ingelheim. Boehringer Ingelheim has had no influence over the content. This educational hub is not intended for UK or IRELAND based physicians.
Source: www.radcliffecardiology.comCategories: Latest Headlines, Partners & KOLsTweet-
Thank you for joining #EASDRME at #EASD2023. Don't forget to check out our educational videos on our obesity resource ➡️ https://t.co/TCGG2h5gDL @conscienHealth @BevTchangMD @EasoPresident @DrKarlNadolsky @MWeintraubMD ✖️ Not intended for UK and Ireland based Healthcare… https://t.co/UBJRj5DjwQ
-
-
Mashup Score: 0Adults with obesity using tirzepatide maintain ‘remarkable’ weight loss at 88 weeks - 7 month(s) ago
Adults with obesity receiving tirzepatide lost more than 25% of their body weight and were able to maintain their weight loss for up to 88 weeks, according to data from the SURMOUNT-4 trial. In SURMOUNT-4, all participants received tirzepatide (Mounjaro, Eli Lilly) during a lead-in phase, with the study population achieving a mean weight loss of 20.2% at 36 weeks. At 36 weeks, participants were
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
Weight loss achieved with tirzepatide at 36 weeks was maintained for adults with #obesity who continued to use the agent for up to 88 weeks, according to data from the SURMOUNT-4 trial presented at #EASD2023. @ljaronne @EASDnews #EndoTwitter https://t.co/osJX0op7p8
-
Recordings from #EASD2023 now publicly available in the EASD Media Centre! https://t.co/FdUWgztChu Take advantage of this invaluable resource and browse through 1,000's of recordings from EASD's Annual Meetings. https://t.co/ceuN5WFj0P